Download PDF
CC BY 4.0 · Glob Med Genet 2022; 09(03): 191-199
DOI: 10.1055/s-0042-1748170
Original Article

SARS-CoV-2-Induced Immunosuppression: A Molecular Mimicry Syndrome

Darja Kanduc 
1   Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Bari, Italy
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background Contrary to immunological expectations, decay of adaptive responses against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) characterizes recovered patients compared with patients who had a severe disease course or died following SARS-CoV-2 infection. This raises the question of the causes of the virus-induced immune immunosuppression. Searching for molecular link(s) between SARS-CoV-2 immunization and the decay of the adaptive immune responses, SARS-CoV-2 proteome was analyzed for molecular mimicry with human proteins related to immunodeficiency. The aim was to verify the possibility of cross-reactions capable of destroying the adaptive immune response triggered by SARS-CoV-2.

Materials and Methods Human immunodeficiency–related proteins were collected from UniProt database and analyzed for sharing of minimal immune determinants with the SARS-CoV-2 proteome.

Results Molecular mimicry and consequent potential cross-reactivity exist between SARS-CoV-2 proteome and human immunoregulatory proteins such as nuclear factor kappa B (NFKB), and variable diversity joining V(D)J recombination-activating gene (RAG).

Conclusion The data (1) support molecular mimicry and the associated potential cross-reactivity as a mechanism that can underlie self-reactivity against proteins involved in B- and T-cells activation/development, and (2) suggest that the extent of the immunosuppression is dictated by the extent of the immune responses themselves. The higher the titer of the immune responses triggered by SARS-CoV-2 immunization, the more severe can be the cross-reactions against the human immunodeficiency–related proteins, the more severe the immunosuppression. Hence, SARS-CoV-2-induced immunosuppression can be defined as a molecular mimicry syndrome. Clinically, the data imply that booster doses of SARS-CoV-2 vaccines may have opposite results to those expected.

Keywords

SARS-CoV-2 - immunosuppression - molecular mimicry - cross-reactivity - NFKB - V(D)J RAG proteins

Supplementary Material



Publication History

Article published online:
14 July 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Stuttgart · New York

 

  • References

  • 1 Lipsitch M, Krammer F, Regev-Yochay G, Lustig Y, Balicer RD. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nat Rev Immunol 2022; 22 (01) 57-65
    CrossrefPubMedGoogle Scholar
  • 2 Jo DH, Minn D, Lim J. et al. Rapidly declining SARS-CoV-2 antibody titers within 4 months after BNT162b2 vaccination. Vaccines (Basel) 2021; 9 (10) 1145
    CrossrefPubMedGoogle Scholar
  • 3 Israel A, Merzon E, Schäffer AA. et al. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study. BMJ 2021; 375: e067873
    CrossrefPubMedGoogle Scholar
  • 4 Israel A, Shenhar Y, Green I. et al. Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection. Vaccines (Basel) 2021; 10 (01) 64
    CrossrefPubMedGoogle Scholar
  • 5 Achiron A, Mandel M, Dreyer-Alster S, Harari G, Gurevich M. Humoral SARS-COV-2 IgG decay within 6 months in COVID-19 healthy vaccinees: The need for a booster vaccine dose?. Eur J Intern Med 2021; 94: 105-107
    CrossrefPubMedGoogle Scholar
  • 6 Krutikov M, Palmer T, Tut G. et al. Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England. Lancet Healthy Longev 2022; 3 (01) e13-e21
    CrossrefPubMedGoogle Scholar
  • 7 Seow J, Graham C, Merrick B. et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol 2020; 5 (12) 1598-1607
    CrossrefPubMedGoogle Scholar
  • 8 Ibarrondo FJ, Fulcher JA, Goodman-Meza D. et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild COVID-19. N Engl J Med 2020; 383 (11) 1085-1087
    CrossrefPubMedGoogle Scholar
  • 9 Van Elslande J, Oyaert M, Ailliet S. et al. Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection. J Clin Virol 2021; 136: 104765
    CrossrefPubMedGoogle Scholar
  • 10 Alfego D, Sullivan A, Poirier B, Williams J, Adcock D, Letovsky S. A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States. EClinicalMedicine 2021; 36: 100902
    CrossrefPubMedGoogle Scholar
  • 11 Lee E, Oh JE. Humoral immunity against SARS-CoV-2 and the impact on COVID-19 pathogenesis. Mol Cells 2021; 44 (06) 392-400
    CrossrefPubMedGoogle Scholar
  • 12 Röltgen K, Powell AE, Wirz OF. et al. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol 2020; 5 (54) eabe0240
    CrossrefPubMedGoogle Scholar
  • 13 Garcia-Beltran WF, Lam EC, Astudillo MG. et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell 2021; 184 (02) 476-488.e11
    CrossrefPubMedGoogle Scholar
  • 14 Hashem AM, Algaissi A, Almahboub SA. et al. Early humoral response correlates with disease severity and outcomes in COVID-19 patients. Viruses 2020; 12 (12) 1390
    CrossrefPubMedGoogle Scholar
  • 15 Wang Y, Zhang L, Sang L. et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. J Clin Invest 2020; 130 (10) 5235-5244
    CrossrefPubMedGoogle Scholar
  • 16 Zhao J, Yuan Q, Wang H. et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin Infect Dis 2020; 71 (16) 2027-2034
    CrossrefPubMedGoogle Scholar
  • 17 Van Elslande J, Gruwier L, Godderis L, Vermeersch P. Estimated half-life of SARS-CoV-2 anti-spike antibodies more than double the half-life of anti-nucleocapsid antibodies in healthcare workers. Clin Infect Dis 2021; 73 (12) 2366-2368
    CrossrefPubMedGoogle Scholar
  • 18 Chansaenroj J, Yorsaeng R, Posuwan N. et al. Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients. Sci Rep 2021; 11 (01) 23216
    CrossrefPubMedGoogle Scholar
  • 19 Batra M, Tian R, Zhang C. et al. Role of IgG against N-protein of SARS-CoV2 in COVID19 clinical outcomes. Sci Rep 2021; 11 (01) 3455
    CrossrefPubMedGoogle Scholar
  • 20 Habel JR, Nguyen THO, van de Sandt CE. et al. Suboptimal SARS-CoV-2-specific CD8+ T cell response associated with the prominent HLA-A*02:01 phenotype. Proc Natl Acad Sci U S A 2020; 117 (39) 24384-24391
    CrossrefPubMedGoogle Scholar
  • 21 Yang J, Zhong M, Hong K. et al. Characteristics of T-cell responses in COVID-19 patients with prolonged SARS-CoV-2 positivity - a cohort study. Clin Transl Immunology 2021; 10 (03) e1259
    CrossrefPubMedGoogle Scholar
  • 22 Cohen CA, Li APY, Hachim A. et al. SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection. Nat Commun 2021; 12 (01) 4678
    CrossrefPubMedGoogle Scholar
  • 23 Krüttgen A, Klingel H, Haase G, Haefner H, Imöhl M, Kleines M. Evaluation of the QuantiFERON SARS-CoV-2 interferon-ɣ release assay in mRNA-1273 vaccinated health care workers. J Virol Methods 2021; 298: 114295
    CrossrefPubMedGoogle Scholar
  • 24 Specter S, Bendinelli M, Friedman H. Virus-Induced Immunosuppression. New York, NY: Plenum Press; 1989: 1-477
    CrossrefGoogle Scholar
  • 25 Kanduc D. From Anti-SARS-CoV-2 Immune responses to COVID-19 via molecular mimicry. Antibodies (Basel) 2020; 9 (03) 33
    CrossrefPubMedGoogle Scholar
  • 26 Kanduc D. Thromboses and hemostasis disorders associated with COVID-19: The possible causal role of cross-reactivity and immunological imprinting. Glob Med Genet 2021; 8 (04) 162-170
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Kanduc D. Measles virus hemagglutinin epitopes are potential hotspots for crossreactions with immunodeficiency-related proteins. Future Microbiol 2015; 10 (04) 503-515
    CrossrefPubMedGoogle Scholar
  • 28 Reddehase MJ, Rothbard JB, Koszinowski UH. A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes. Nature 1989; 337 (6208): 651-653
    CrossrefPubMedGoogle Scholar
  • 29 Zagury JF, Bernard J, Achour A. et al. Identification of CD4 and major histocompatibility complex functional peptide sites and their homology with oligopeptides from human immunodeficiency virus type 1 glycoprotein gp120: role in AIDS pathogenesis. Proc Natl Acad Sci U S A 1993; 90 (16) 7573-7577
    CrossrefPubMedGoogle Scholar
  • 30 Gulden PH, Fischer III P, Sherman NE. et al. A Listeria monocytogenes pentapeptide is presented to cytolytic T lymphocytes by the H2-M3 MHC class Ib molecule. Immunity 1996; 5 (01) 73-79
    CrossrefPubMedGoogle Scholar
  • 31 Malarkannan S, Gonzalez F, Nguyen V, Adair G, Shastri N. Alloreactive CD8+ T cells can recognize unusual, rare, and unique processed peptide/MHC complexes. J Immunol 1996; 157 (10) 4464-4473
    CrossrefPubMedGoogle Scholar
  • 32 Byers DE, Fischer Lindahl K. H2-M3 presents a nonformylated viral epitope to CTLs generated in vitro. J Immunol 1998; 161 (01) 90-96
    CrossrefPubMedGoogle Scholar
  • 33 Lockey TD, Surman S, Brown S. et al. A five-residue HIV envelope helper T cell determinant: does this peptide-MHC interaction leave the binding groove half empty?. AIDS Res Hum Retroviruses 2002; 18 (15) 1141-1144
    CrossrefPubMedGoogle Scholar
  • 34 Pieczenik G. Are the universes of antibodies and antigens symmetrical?. Reprod Biomed Online 2003; 6 (02) 154-156
    CrossrefPubMedGoogle Scholar
  • 35 Glithero A, Tormo J, Doering K, Kojima M, Jones EY, Elliott T. The crystal structure of H-2D(b) complexed with a partial peptide epitope suggests a major histocompatibility complex class I assembly intermediate. J Biol Chem 2006; 281 (18) 12699-12704
    CrossrefPubMedGoogle Scholar
  • 36 Kanduc D. Homology, similarity, and identity in peptide epitope immunodefinition. J Pept Sci 2012; 18 (08) 487-494
    CrossrefPubMedGoogle Scholar
  • 37 Raychaudhuri S, Sandor C, Stahl EA. et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet 2012; 44 (03) 291-296
    CrossrefPubMedGoogle Scholar
  • 38 Zeng W, Pagnon J, Jackson DC. The C-terminal pentapeptide of LHRH is a dominant B cell epitope with antigenic and biological function. Mol Immunol 2007; 44 (15) 3724-3731
    CrossrefPubMedGoogle Scholar
  • 39 Koch CP, Perna AM, Pillong M. et al. Scrutinizing MHC-I binding peptides and their limits of variation. PLOS Comput Biol 2013; 9 (06) e1003088
    CrossrefPubMedGoogle Scholar
  • 40 Kanduc D. Pentapeptides as minimal functional units in cell biology and immunology. Curr Protein Pept Sci 2013; 14 (02) 111-120
    CrossrefPubMedGoogle Scholar
  • 41 Morita D, Yamamoto Y, Suzuki J, Mori N, Igarashi T, Sugita M. Molecular requirements for T cell recognition of N-myristoylated peptides derived from the simian immunodeficiency virus Nef protein. J Virol 2013; 87 (01) 482-488
    CrossrefPubMedGoogle Scholar
  • 42 Hao SS, Zong MM, Zhang Z. et al. The inducing roles of the new isolated bursal hexapeptide and pentapeptide on the immune response of AIV vaccine in mice. Protein Pept Lett 2019; 26 (07) 542-549
    CrossrefPubMedGoogle Scholar
  • 43 Yamamoto Y, Morita D, Shima Y. et al. Identification and structure of an MHC Class I-encoded protein with the potential to present N-myristoylated 4-mer peptides to T cells. J Immunol 2019; 202 (12) 3349-3358
    CrossrefPubMedGoogle Scholar
  • 44 Kanduc D. Hydrophobicity and the physico-chemical basis of immunotolerance. Pathobiology 2020; 87 (04) 268-276
    CrossrefPubMedGoogle Scholar
  • 45 Kanduc D. The role of proteomics in defining autoimmunity. Expert Rev Proteomics 2021; 18 (03) 177-184
    CrossrefPubMedGoogle Scholar
  • 46 Asano T, Kaneko MK, Takei J, Tateyama N, Kato Y. Epitope mapping of the anti-CD44 monoclonal antibody (C44Mab-46) using the REMAP method. Monoclon Antib Immunodiagn Immunother 2021; 40 (04) 156-161
    CrossrefPubMedGoogle Scholar
  • 47 Hemed-Shaked M, Cowman MK, Kim JR. et al. MTADV 5-MER peptide suppresses chronic inflammations as well as autoimmune pathologies and unveils a new potential target-serum amyloid A. J Autoimmun 2021; 124: 102713
    CrossrefPubMedGoogle Scholar
  • 48 UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res 2019; 47 (D1) D506-D515
    CrossrefPubMedGoogle Scholar
  • 49 Chen C, Li Z, Huang H, Suzek BE, Wu CH. UniProt Consortium. A fast peptide match service for UniProt knowledgebase. Bioinformatics 2013; 29 (21) 2808-2809
    CrossrefPubMedGoogle Scholar
  • 50 Salimi N, Edwards L, Foos G. et al. A behind-the-scenes tour of the IEDB curation process: an optimized process empirically integrating automation and human curation efforts. Immunology 2020; 161 (02) 139-147
    CrossrefPubMedGoogle Scholar
  • 51 Choudhry H, Bakhrebah MA, Abdulaal WH. et al. Middle East respiratory syndrome: pathogenesis and therapeutic developments. Future Virol 2019; 14 (04) 237-246
    CrossrefPubMedGoogle Scholar
  • 52 Su S, Wong G, Shi W. et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 2016; 24 (06) 490-502
    CrossrefPubMedGoogle Scholar
  • 53 Pomerantz JL, Denny EM, Baltimore D. CARD11 mediates factor-specific activation of NF-kappaB by the T cell receptor complex. EMBO J 2002; 21 (19) 5184-5194
    CrossrefPubMedGoogle Scholar
  • 54 Hutcherson SM, Bedsaul JR, Pomerantz JL. Pathway-specific defects in T, B, and NK Cells and age-dependent development of high IgE in mice heterozygous for a CADINS-associated dominant negative CARD11 allele. J Immunol 2021; 207 (04) 1150-1164
    CrossrefPubMedGoogle Scholar
  • 55 Hara H, Wada T, Bakal C. et al. The MAGUK family protein CARD11 is essential for lymphocyte activation. Immunity 2003; 18 (06) 763-775
    CrossrefPubMedGoogle Scholar
  • 56 Jeelall YS, Wang JQ, Law HD. et al. Human lymphoma mutations reveal CARD11 as the switch between self-antigen-induced B cell death or proliferation and autoantibody production. J Exp Med 2012; 209 (11) 1907-1917
    CrossrefPubMedGoogle Scholar
  • 57 Stepensky P, Keller B, Buchta M. et al. Deficiency of caspase recruitment domain family, member 11 (CARD11), causes profound combined immunodeficiency in human subjects. J Allergy Clin Immunol 2013; 131 (02) 477-85.e1
    CrossrefPubMedGoogle Scholar
  • 58 Vale AM, Schroeder Jr HW. Clinical consequences of defects in B-cell development. J Allergy Clin Immunol 2010; 125 (04) 778-787
    CrossrefPubMedGoogle Scholar
  • 59 van Zelm MC, Reisli I, van der Burg M. et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med 2006; 354 (18) 1901-1912
    CrossrefPubMedGoogle Scholar
  • 60 Kuijpers TW, Bende RJ, Baars PA. et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest 2010; 120 (01) 214-222
    CrossrefPubMedGoogle Scholar
  • 61 Abolhassani H. Specific immune response and cytokine production in CD70 deficiency. Front Pediatr 2021; 9: 615724
    CrossrefPubMedGoogle Scholar
  • 62 Oettinger MA, Schatz DG, Gorka C, Baltimore D. RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J recombination. Science 1990; 248 (4962): 1517-1523
    CrossrefPubMedGoogle Scholar
  • 63 Villa A, Sobacchi C, Notarangelo LD. et al. V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Blood 2001; 97 (01) 81-88
    CrossrefPubMedGoogle Scholar
  • 64 Gennery A. Recent advances in understanding RAG deficiencies. F1000 Res 2019; 8: F1000
    CrossrefPubMedGoogle Scholar
  • 65 Dieli-Crimi R, Martínez-Gallo M, Franco-Jarava C. et al. Th1-skewed profile and excessive production of proinflammatory cytokines in a NFKB1-deficient patient with CVID and severe gastrointestinal manifestations. Clin Immunol 2018; 195: 49-58
    CrossrefPubMedGoogle Scholar
  • 66 Fliegauf M, Bryant VL, Frede N. et al. Haploinsufficiency of the NF-κB1 subunit p50 in common variable immunodeficiency. Am J Hum Genet 2015; 97 (03) 389-403
    CrossrefPubMedGoogle Scholar
  • 67 Chen K, Coonrod EM, Kumánovics A. et al. Germline mutations in NFKB2 implicate the noncanonical NF-κB pathway in the pathogenesis of common variable immunodeficiency. Am J Hum Genet 2013; 93 (05) 812-824
    CrossrefPubMedGoogle Scholar
  • 68 Franzoso G, Carlson L, Poljak L. et al. Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J Exp Med 1998; 187 (02) 147-159
    CrossrefPubMedGoogle Scholar
  • 69 Lo JC, Basak S, James ES. et al. Coordination between NF-kappaB family members p50 and p52 is essential for mediating LTbetaR signals in the development and organization of secondary lymphoid tissues. Blood 2006; 107 (03) 1048-1055
    CrossrefPubMedGoogle Scholar
  • 70 Ruddle NH, Akirav EM. Secondary lymphoid organs: responding to genetic and environmental cues in ontogeny and the immune response. J Immunol 2009; 183 (04) 2205-2212
    CrossrefPubMedGoogle Scholar
  • 71 Kuehn HS, Bernasconi A, Niemela JE. et al. A nonsense N-terminus NFKB2 mutation leading to haploinsufficiency in a patient with a predominantly antibody deficiency. J Clin Immunol 2020; 40 (08) 1093-1101
    CrossrefPubMedGoogle Scholar
  • 72 Kanduc D. Peptide cross-reactivity: the original sin of vaccines. Front Biosci (Schol Ed) 2012; 4 (04) 1393-1401
    CrossrefPubMedGoogle Scholar